A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
Condition(s):Overactive Bladder (OAB)Last Updated:February 26, 2020Completed
Hide Studies Not Open or Pending
Condition(s):Overactive Bladder (OAB)Last Updated:February 26, 2020Completed
Condition(s):Overactive BladderLast Updated:April 4, 2018Terminated
Condition(s):Urinary Incontinence; Fecal Incontinence; Urge Incontinence; Nocturia; Urinary Frequency More Than Once at Night; Bowel Disorders Functional; Urinary Incontinence, Urge; Incontinence, Nighttime UrinaryLast Updated:February 5, 2024Completed
Condition(s):Autosomal Dominant Polycystic Kidney Disease; Nephrogenic Diabetes Insipidus; Acquired Nephrogenic Diabetes Insipidus; Congenital Nephrogenic Diabetes InsipidusLast Updated:January 19, 2023Recruiting
Condition(s):Overactive Bladder; Urinary IncontinenceLast Updated:November 2, 2018Completed
Condition(s):Overactive BladderLast Updated:September 15, 2009Completed
Condition(s):Urinary Tract InfectionLast Updated:October 27, 2017Terminated
Condition(s):Overactive Bladder Syndrome; Multiple Sclerosis; Muscle StrainLast Updated:January 10, 2018Unknown status
Condition(s):Overactive Bladder; Urge Incontinence; Urinary Incontinence; Urinary Frequency More Than Once at NightLast Updated:March 23, 2021Completed
Condition(s):Urinary Tract Infections; Catheter-Related InfectionsLast Updated:February 25, 2022Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.